JP Patent

JP2016519128A — Ｇｌｐ−１化合物の経口投薬

Assigned to Novo Nordisk AS · Expires 2016-06-30 · 10y expired

What this patent protects

本発明は、経口療法におけるGLP-1ペプチドの改善された使用に関する。

USPTO Abstract

本発明は、経口療法におけるGLP-1ペプチドの改善された使用に関する。

Drugs covered by this patent

Patent Metadata

Patent number
JP2016519128A
Jurisdiction
JP
Classification
—
Expires
2016-06-30
Drug substance claim
No
Drug product claim
No
Assignee
Novo Nordisk AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.